申请人:MOCHIDA PHARMACEUTICAL CO., LTD.
公开号:EP1182192A1
公开(公告)日:2002-02-27
The present invention relates to a compound represented by the following formula (I) or a salt thereof, or a pharmaceutical composition containing the compound as an effective ingredient:
(wherein A represents, for example, phenyl group substituted with R1 and R2 or unsubstituted thienyl group; R1 and R2 each independently represent, for example, hydrogen atom, halogen atom or lower alkoxycarbonyl group; R3 represents, for example, hydrogen atom; R4 represents, for example, lower alkyl group; R5 represents, for example, lower alkoxy group; R6 represents, for example, hydrogen atom; R7 and R8 each represent, for example, hydrogen atom, respectively; X represents, for example, a single bond; Y represents, for example, methylene group or benzylidene group substituted with R1; and Z represents, for example, methylene group.) The compounds according to the present invention that do not suppress the transient sodium current of the cardiac muscle and do not manifest proarrhythimic activity is useful as a therapeutic agent for preventing and/or treating arrhythimia and for preventing sudden death.
本发明涉及下式(I)代表的化合物或其盐,或含有该化合物作为有效成分的药物组合物:
(其中 A 代表例如被 R1 和 R2 取代的苯基或未取代的噻吩基;R1 和 R2 各自独立地代表例如氢原子、卤素原子或低级烷氧羰基;R3 代表例如氢原子;R4 代表例如低级烷基;R5 代表例如低级烷氧基; R6 代表例如氢原子; R7 和 R8 分别代表例如氢原子; X 代表例如单键; Y 代表例如亚甲基或被 R1 取代的亚苄基;以及 Z 代表例如亚甲基。)根据本发明的化合物不抑制心肌的瞬态钠电流,不表现出促心律失常活性,可作为预防和/或治疗心律失常和预防猝死的治疗剂。